Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.

CONCLUSIONS: This study found that the addition of omalizumab is not a cost-effective strategy compared with standard therapy for children with severe allergic asthma in China due to its high cost. PMID: 30507328 [PubMed - as supplied by publisher] (Source: Journal of Asthma)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2AZ1Nhn